Abatacept (CTLA4 Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)

Abatacept (CTLA4 Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)

Brief description of study

This is a clinical trial to determine the effectiveness and safety of the investigational drug, abatacept, in treating patients with granulomatosis with polyangiitis (GPA). GPA is a disease that causes swelling of the blood vessels (vasculitis). We are looking for participants with GPA who have had a disease flare (relapse) in the past 4 weeks. Enrolled participants will be randomized (like flipping a coin) to receive either abatacept or placebo (liquid that looks like the study drug but contains no medication). Participants will inject the abatacept or placebo one time a week for 1 year, and will have clinic visits every 3 months.

Detailed description of study

At each visit, participants will have a physical exam, answer questionnaires, and give blood and urine samples. It is possible to be in this study for up to 4 years. This study is a project of the Vasculitis Clinical Research Consortium (VCRC), which is a consortium of investigators in major North American vasculitis centers. The VCRC is funded through the National Institutes of Health as a Rare Diseases Clinical Research Network with the purpose of promoting research in vasculitis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Vasculitis,Wegener's granulomatosis,Antibodies,Anti-Neutrophil Cytoplasmic,Anti neutrophilic cytoplasm antibody,Anti Neutrophil Cytoplasmic Antibody,Neutrophil cytoplasmic Ab,Antibody,Antineutrophil Cytoplasmic,Antibodies,Antineutrophil Cytoplasmic [Chemical/Ingredient],Anti-Neutrophil Cytoplasmic Antibodies,Anti-Neutrophil Cytoplasmic Antibody,Anti neutrophilic cytoplasm antibody (substance),Antibody,Anti-Neutrophil Cytoplasmic,Antineutrophil Cytoplasmic Antibodies,ANCA - Anti-neutroph cytopl ab,Antineutrophil cytoplasm antib,Anti Neutrophil Cytoplasmic Antibodies,Neutrophil cytoplasmic antibody,ANCA - Anti-neutrophil cytoplasmic antibody,Cytoplasmic Antibodies,Antineutrophil,antineutrophil cytoplasmic antibody (ANCA),Antineutrophil Cytoplasmic Antibody,Antibodies,Antineutrophil Cytoplasmic,Cytoplasmic Antibody,Anti-Neutrophil,Cytoplasmic Antibodies,Anti-Neutrophil,ANCA,Anticytoplasmic Neutrophil Antibody,Cytoplasmic Antibody,Antineutrophil,Granulomatosis with Polyangiit
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 14 Jul 2023. Study ID: 820678

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center